Sodium phenylbutyrate - Acer Therapeutics

Drug Profile

Sodium phenylbutyrate - Acer Therapeutics

Alternative Names: ACER 001

Latest Information Update: 31 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baylor College of Medicine
  • Developer Acer Therapeutics
  • Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
  • Mechanism of Action Ammonia scavengers; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Maple syrup urine disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Inborn urea cycle disorders; Maple syrup urine disease

Most Recent Events

  • 30 Mar 2017 Chemical structure information added
  • 16 May 2016 Acer Therapeutics plans clinical trials for Inborn urea cycle disorders and Maple syrup urine disease in USA (Acer Therapeutics website, May 2016)
  • 10 May 2016 Phase-II clinical trials in Inborn urea cycle disorders in USA (Parenteral) (Acer Therapeutics pipeline, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top